Skip to main content
ADCT
NYSE Life Sciences

ADC Therapeutics Registers 9.83M Shares for Resale by Institutional Investor, Creating Potential Overhang

Analysis by Wiseek.ai
Sentiment info
Neutral
Importance info
7
Price
$4.22
Mkt Cap
$536.127M
52W Low
$1.05
52W High
$4.98
Market data snapshot near publication time

summarizeSummary

ADC Therapeutics has registered 9.83 million common shares for resale by institutional investor HealthCare Royalty Management, LLC, which were issued from warrants, potentially creating a stock overhang.


check_boxKey Events

  • Registration of Shares for Resale

    ADC Therapeutics SA has registered 9,834,776 common shares for potential resale by HealthCare Royalty Management, LLC (HCR).

  • Origin of Shares from Warrants

    These shares are issuable upon the exercise of warrants that were issued to HCR on February 18, 2026, in connection with an amendment to a Purchase and Sale Agreement.

  • Company Not Receiving Resale Proceeds

    The company will not receive any proceeds from the sale of these common shares by the selling shareholder.

  • Potential Cash from Warrant Exercise

    If the warrants are exercised in cash, the company may receive up to an aggregate of $37.5 million, which would be used for working capital and general corporate purposes.


auto_awesomeAnalysis

This 424B3 filing registers a substantial block of 9,834,776 common shares for resale by HealthCare Royalty Management, LLC (HCR), an institutional investor. These shares originate from warrants issued to HCR on February 18, 2026, and disclosed in a subsequent 8-K filing. While the company will not receive any proceeds from HCR's sale of these shares, it could receive up to $37.5 million if HCR exercises the warrants for cash. The registration of shares representing approximately 7.7% of the company's current market capitalization creates a potential overhang on the stock, as HCR now has the ability to sell these shares into the market. Investors should monitor any future sales activity by HCR.

At the time of this filing, ADCT was trading at $4.22 on NYSE in the Life Sciences sector, with a market capitalization of approximately $536.1M. The 52-week trading range was $1.05 to $4.98. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed ADCT - Latest Insights

ADCT
Apr 20, 2026, 8:33 AM EDT
Filing Type: DEF 14A
Importance Score:
9
ADCT
Apr 10, 2026, 4:15 PM EDT
Filing Type: PRE 14A
Importance Score:
9
ADCT
Mar 16, 2026, 5:02 PM EDT
Filing Type: 424B3
Importance Score:
7
ADCT
Mar 10, 2026, 4:36 PM EDT
Filing Type: 10-K
Importance Score:
7
ADCT
Mar 10, 2026, 7:58 AM EDT
Filing Type: 8-K
Importance Score:
8
ADCT
Mar 10, 2026, 7:30 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
ADCT
Feb 23, 2026, 7:15 AM EST
Filing Type: 8-K
Importance Score:
8
ADCT
Jan 12, 2026, 8:37 AM EST
Filing Type: 8-K
Importance Score:
8
ADCT
Jan 08, 2026, 5:04 PM EST
Filing Type: 8-K
Importance Score:
8